Pronestyl injection and URO-MP Capsules
Determining the interaction of Pronestyl injection and URO-MP Capsules and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR CLOSELY: The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing. It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes. The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Severe and potentially fatal cases of electrolyte disorders and arrhythmias have been reported in elderly patients using bowel cleansing products. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation. MANAGEMENT: Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process. Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. References "Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate)." Fleet, CB, Lynchburg, VA. Cerner Multum, Inc. "Australian Product Information." O 0 Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347 "Product Information. Visicol (sodium biphosphate-sodium phosphate)." Salix Pharmaceuticals, Raleigh, NC. View all 5 references
Professional:MONITOR CLOSELY: The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing. It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.
The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Severe and potentially fatal cases of electrolyte disorders and arrhythmias have been reported in elderly patients using bowel cleansing products. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.
MANAGEMENT: Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process. Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
- "Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate)." Fleet, CB, Lynchburg, VA.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347
- "Product Information. Visicol (sodium biphosphate-sodium phosphate)." Salix Pharmaceuticals, Raleigh, NC.
Generic Name: procainamide
Brand name: Pronestyl, Procan SR, Pronestyl-SR, Procanbid
Synonyms: Pronestyl (injection), Pronestyl
Generic Name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium biphosphate
Brand name: Azuphen MB, Hyolev MB, Phosphasal, UR N-C, Uramit MB, Urelle, Uribel, Urimar-T, Urin D/S, Uro-L, Ustell, Utira-C, Uro-MP, Vilamit MB, Vilevev MB, UR N-C, Urelle, Uretron D/S, Urin DS, Uro-458, UroAv-81, UroAv-B, Uticap, Utrona-C
Synonyms: Hyoscyamine, methenamine, methylene blue, phenyl salicylate, sodium biphosphate, Methenamine, Sodium Phosphate Monobasic, Phenyl Salicylate, Methylene Blue, and Hyoscyamine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Pronestyl injection-UroAv-81
- Pronestyl injection-UroAv-B
- Pronestyl injection-Urocit-K
- Pronestyl injection-Urocit-K 10
- Pronestyl injection-Urocit-K 10 Oral
- Pronestyl injection-Urocit-K 15
- URO-MP Capsules-Pronestyl-SR
- URO-MP Capsules-Pronutrients Vitamin D3
- URO-MP Capsules-Propa pH Acne Med Cleansing
- URO-MP Capsules-Propa pH Topical
- URO-MP Capsules-Propafenone
- URO-MP Capsules-Propafenone Extended Release Capsule